MetaCap

Seaport Therapeutics Inc. (SPTX)

NASDAQ: SPTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

18.05-0.27 (-1.47%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SPTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$966.23M
EPS (TTM)
-$4.35
52-week range
14.85 – 28.38
Day range
17.41 – 18.83
Volume / Avg
284.27K / 259.83K
Beta
—

52-week range

$14.85$28.38

SPTX stock today

On Nov 20, SPTX ended the session at $18.05, shedding $0.27 (1.47%), versus the S&P 500's 3.70% decline. Shares are 36.4% below their 52-week high of $28.38, set on Aug 27, 2026 and 21.5% above the 52-week low of $14.85, in the middle of the past year's range. Seaport Therapeutics has posted a net loss over the last twelve months (EPS of -$4.35), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Seaport Therapeutics

Company profile

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Daphne Zohar
Headquarters
Boston, MA
Employees
59
IPO year
2026

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$37.13+105.71%

  • Strong buy 1
  • Buy 7
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $28.00High $50.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$-0.49 vs $-0.58
Surprise
+15.52%

SPTX news

All SPTX news

Seaport Therapeutics peers

Health Care sector
SPTX peer companies
CompanyPrice% ChgMarket capCompare
OMEROmeros Corporation13.21-5.71%$983.66Mvs SPTX
CYRXCryoPort Inc.19.05-2.56%$964.87Mvs SPTX
ANROAlto Neuroscience Inc.25.37-4.30%$1.02Bvs SPTX
MLTXMoonLake Immunotherapeutics Class A11.07+0.36%$942.13Mvs SPTX
SVRASavara Inc.4.26-18.23%$939.86Mvs SPTX
CTYCity Therapeutics Inc.19.32+5.29%$1.03Bvs SPTX
NKTRNektar Therapeutics30.20-7.19%$1.03Bvs SPTX
JBIOJade Biosciences Inc.15.31+1.66%$1.06Bvs SPTX

Indexes, lists and sector

Seaport Therapeutics stock FAQ

What is Seaport Therapeutics's stock price today?

SPTX last traded at $18.05 as of Nov 20, 4:00 PM EST, down 1.47% on the day. Prices are delayed at least 15 minutes.

Who is Seaport Therapeutics's CEO?

Ms. Daphne Zohar is the chief executive officer of Seaport Therapeutics Inc., which has about 59 employees.

What is the SPTX 52-week high?

The 52-week high for SPTX is $28.38 and the 52-week low is $14.85. The stock is currently 36.4% below its high.

Compare SPTX